0JZU Stock Chart & Stats
$835.65
$18.94(2.27%)
At close: 4:00 PM EDT
$835.65
$18.94(2.27%)
Day’s Range― - ―
52-Week Range$637.29 - $1,016.97
Previous CloseN/A
Volume69.00
Average Volume (3M)1.08K
Market Cap
$100.24B
Enterprise Value$99.54K
Total Cash (Recent Filing)$5.16B
Total Debt (Recent Filing)$11.70B
Price to Earnings (P/E)22.2
Beta0.45
Next Earnings
Nov 03, 2026EPS Estimate
10.75Next Dividend Ex-DateN/A
Dividend Yield0.38%
Share Statistics
EPS (TTM)37.53
Shares Outstanding117,077,740
10 Day Avg. Volume256
30 Day Avg. Volume1,084
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)-49.24
Price to Sales (P/S)0.27
P/FCF Ratio18.70
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$970.75Price Target Upside16.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)44.26
Revenue Forecast (FY)$431.21B
Bulls Say, Bears Say
Bulls Say
Cash GenerationSustained high operating and free cash flow provides durable internal funding for buybacks, dividends, M&A and separation costs. Strong cash conversion (~0.98x) reduces reliance on external financing, supporting capital returns and flexibility through margin cycles and industry volatility.
Scale & Distribution NetworkExtensive scale across retail, health systems and specialty distribution delivers purchasing leverage, stable contract flows and network effects. Large volume footprint and long-term customer relationships create durable competitive advantage against smaller distributors and support resilience across product cycles.
Specialty / Biopharma MomentumRapid growth in oncology, specialty drugs and biopharma services diversifies revenue mix into higher-value, service-intensive areas. Scale in verifications and provider additions improves sticky service economics and raises structural growth potential less tied to low-margin commodity distribution.
Bears Say
Negative Shareholder EquityPersistently negative equity weakens capital structure and reduces financial flexibility, making leverage and solvency metrics harder to interpret. In stressed scenarios this raises refinancing and covenant risks, constrains strategic options and can magnify downside for equity holders.
Thin, Compressing MarginsVery low distributor gross margins leave limited buffer for pricing pressure, supplier cost shifts or mix swings. Margin compression historically noted increases sensitivity to branded/generic mix, IRA-driven pricing and specialty mix variability, making earnings volatile despite scale.
Separation Financing & Interest HeadwindsSeparation financing raises interest costs and covenant exposure for the Medical‑Surgical carve‑out and the parent. Incremental debt and higher interest expense reduce consolidated free cash flow and increase execution risk during separation, pressuring near‑term liquidity and flexibility.
McKesson News
0JZU FAQ
What was Mckesson Corp.’s price range in the past 12 months?
Mckesson Corp. lowest share price was $637.28 and its highest was $1016.97 in the past 12 months.
What is Mckesson Corp.’s market cap?
Mckesson Corp.’s market cap is $100.24B.
When is Mckesson Corp.’s upcoming earnings report date?
Mckesson Corp.’s upcoming earnings report date is Nov 03, 2026 which is in 88 days.
How were Mckesson Corp.’s earnings last quarter?
Mckesson Corp. released its earnings results on Aug 05, 2026. The company reported $9.93 earnings per share for the quarter, beating the consensus estimate of $9.561 by $0.369.
Is Mckesson Corp. overvalued?
According to Wall Street analysts Mckesson Corp.’s price is currently Undervalued.
Does Mckesson Corp. pay dividends?
Mckesson Corp. pays a Quarterly dividend of $0.94 which represents an annual dividend yield of 0.38%. See more information on Mckesson Corp. dividends here
What is Mckesson Corp.’s EPS estimate?
Mckesson Corp.’s EPS estimate is 10.75.
How many shares outstanding does Mckesson Corp. have?
Mckesson Corp. has 117,077,740 shares outstanding.
What happened to Mckesson Corp.’s price movement after its last earnings report?
Mckesson Corp. reported an EPS of $9.93 in its last earnings report, beating expectations of $9.561. Following the earnings report the stock price went up 1.583%.
Which hedge fund is a major shareholder of Mckesson Corp.?
Currently, no hedge funds are holding shares in GB:0JZU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
McKesson Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$970.75 (16.17% Upside)
$970.75 (16.17% Upside)
Blogger Sentiment
Bullish
GB:0JZU Sentiment 78%
Sector Average 63%
Sector Average 63%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
18.88%
12-Months-Change
Fundamentals
Return on Equity
0.38%
Trailing 12-Months
Asset Growth
9.56%
Trailing 12-Months
Company Description
Mckesson Corp.
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
0JZU Company Deck
0JZU Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
McKesson reported a strong fiscal 2026 with double-digit revenue, operating profit and EPS growth, robust cash generation and material progress on strategic initiatives (oncology expansion, biopharma scale, supply chain modernization, and Medical‑Surgical separation). The company is returning significant capital to shareholders and reaffirmed long‑term targets. Offsetting risks include branded pricing pressure (IRA effects), sequential GLP‑1 volatility, ongoing integration and corporate expense investments, and near‑term cash flow/interest impacts related to separation financing. On balance the positives (broad-based growth, margin expansion, cash returns, strategic progress) outweigh the negatives, though the business faces near-term variability and execution/approval risks tied to the Medical‑Surgical separation.View all GB:0JZU earnings summaries0JZU Revenue Breakdown
83.45% North American Pharmaceutical
12.00% Oncology & Multispecialty
1.44% Prescription Technology Solutions
2.85% Medical-Surgical Solutions
0.26% Other
0JZU Stock 12 Month Forecast
Average Price Target
$970.75
▲(16.17% Upside)
Technical Analysis
Cencora
―
Cardinal Health
―
Henry Schein
―
Prestige Consumer Healthcare
―
Guardian Pharmacy Services, Inc. Class A
―